Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2017, Article ID 4537632, 9 pages
https://doi.org/10.1155/2017/4537632
Research Article

Physicochemical Characterization and Cyclodextrin Complexation of the Anticancer Drug Lapatinib

1Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes Endre U. 9, Budapest 1092, Hungary
2Department of Drugs Industry and Pharmaceutical Management, University of Medicine and Pharmacy, Gh. Marinescu 38, 540139 Târgu Mureș, Romania

Correspondence should be addressed to Arash Mirzahosseini; uh.vinu-siewlemmes.amrahp@hsara.iniessohazrim

Received 24 November 2016; Accepted 9 February 2017; Published 1 March 2017

Academic Editor: Jaime Villaverde

Copyright © 2017 Gergő Tóth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. M. Higa and J. Abraham, “Lapatinib in the treatment of breast cancer,” Expert Review of Anticancer Therapy, vol. 7, no. 9, pp. 1183–1192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Johnston, J. Pippen Jr., X. Pivot et al., “Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor—positive metastatic breast cancer,” Journal of Clinical Oncology, vol. 27, no. 33, pp. 5538–5546, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. H. A. Burris III, C. W. Taylor, S. F. Jones et al., “A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies,” Clinical Cancer Research, vol. 15, no. 21, pp. 6702–6708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. L. A. Devriese, K. M. Koch, M. Mergui-Roelvink et al., “Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours,” Investigational New Drugs, vol. 32, no. 3, pp. 481–488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. K. M. Koch, Y.-H. Im, S.-B. Kim et al., “Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients,” Clinical Pharmacology in Drug Development, vol. 2, no. 4, pp. 336–341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Leuner, “Improving drug solubility for oral delivery using solid dispersions,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 47–60, 2000. View at Publisher · View at Google Scholar
  8. R. L. Carrier, L. A. Miller, and I. Ahmed, “The utility of cyclodextrins for enhancing oral bioavailability,” Journal of Controlled Release, vol. 123, no. 2, pp. 78–99, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. K. A. Connors, “The stability of cyclodextrin complexes in solution,” Chemical Reviews, vol. 97, no. 5, pp. 1325–1358, 1997. View at Publisher · View at Google Scholar
  10. J. Szejtli, “Introduction and general overview of cyclodextrin chemistry,” Chemical Reviews, vol. 98, no. 5, pp. 1743–1753, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Loftsson and D. Duchene, “Cyclodextrins and their pharmaceutical applications,” International Journal of Pharmaceutics, vol. 329, no. 1-2, pp. 1–11, 2007. View at Publisher · View at Google Scholar
  12. H. Gao, Y. Wang, C. Chen et al., “Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug,” International Journal of Pharmaceutics, vol. 461, no. 1-2, pp. 478–488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Zhang, S. Zhang, S.-B. Ruan, Q.-Y. Zhang, Q. He, and H.-L. Gao, “Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism,” Acta Pharmacologica Sinica, vol. 35, no. 6, pp. 846–852, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Song, X. Yang, X. Chen, H. Nie, S. Byrn, and J. W. Lubach, “Investigation of drug-excipient interactions in lapatinib amorphous solid dispersions using solid-state NMR spectroscopy,” Molecular Pharmaceutics, vol. 12, no. 3, pp. 857–866, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Béni, Z. Szakács, O. Csernák, L. Barcza, and B. Noszál, “Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities,” European Journal of Pharmaceutical Sciences, vol. 30, no. 2, pp. 167–174, 2007. View at Publisher · View at Google Scholar
  16. Y.-H. Phillip Lee, S. Sathigari, Y.-J. Jean Lin et al., “Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies,” Drug Development and Industrial Pharmacy, vol. 35, no. 9, pp. 1113–1120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Devasari, C. P. Dora, C. Singh et al., “Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: preparation, characterization, in silico, in vitro and in vivo evaluation,” Carbohydrate Polymers, vol. 134, pp. 547–556, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. L. Gontijo, P. P. G. Guimarães, C. T. R. Viana et al., “Erlotinib/hydroxypropyl-β-cyclodextrin inclusion complex: characterization and in vitro and in vivo evaluation,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 83, no. 3-4, pp. 267–279, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Tóth, Á. Jánoska, Z.-I. Szabó et al., “Physicochemical characterisation and cyclodextrin complexation of erlotinib,” Supramolecular Chemistry, vol. 28, no. 7-8, pp. 656–664, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. D. W. Rusnak, K. Lackey, K. Affleck et al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 1, no. 2, pp. 85–94, 2001. View at Google Scholar · View at Scopus
  21. M. J. Sambade, R. J. Kimple, J. T. Camp et al., “Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts,” International Journal of Radiation Oncology, Biology, Physics, vol. 77, no. 2, pp. 575–581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Y. Tam and K. Takács-Novák, “Multi-wavelength spectrophotometric determination of acid dissociation constants: a validation study,” Analytica Chimica Acta, vol. 434, no. 1, pp. 157–167, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Völgyi, R. Ruiz, K. Box, J. Comer, E. Bosch, and K. Takács-Novák, “Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: validation study in a new cosolvent system,” Analytica Chimica Acta, vol. 583, no. 2, pp. 418–428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Stuart and K. Box, “Chasing equilibrium: measuring the intrinsic solubility of weak acids and bases,” Analytical Chemistry, vol. 77, no. 4, pp. 983–990, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Völgyi, E. Baka, K. J. Box, J. E. A. Comer, and K. Takács-Novák, “Study of pH-dependent solubility of organic bases. Revisit of Henderson-Hasselbalch relationship,” Analytica Chimica Acta, vol. 673, no. 1, pp. 40–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Tóth, K. Mazák, S. Hosztafi, J. Kökösi, and B. Noszál, “Species-specific lipophilicity of thyroid hormones and their precursors in view of their membrane transport properties,” Journal of Pharmaceutical and Biomedical Analysis, vol. 76, pp. 112–118, 2013. View at Publisher · View at Google Scholar
  27. T. Higuchi and K. A. Connors, “Phase solubility studies,” in Advances in Analytical Chemistry and Instrumentation, C. N. Reilly, Ed., pp. 117–212, Wiley-Interscience, New York, NY, USA, 1965. View at Google Scholar
  28. K. M. Al Azzam and E. Muhammad, “Host-guest inclusion complexes between mitiglinide and the naturally occurring cyclodextrins α, β, and γ: a theoretical approach,” Advanced Pharmaceutical Bulletin, vol. 5, no. 2, pp. 289–291, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Wen, F. Tan, Z. Jing, and Z. Liu, “Preparation and study the 1:2 inclusion complex of carvedilol with β-cyclodextrin,” Journal of Pharmaceutical and Biomedical Analysis, vol. 34, no. 3, pp. 517–523, 2004. View at Publisher · View at Google Scholar
  30. C. Hansch, “On the future of QSAR,” in Medicinal Chemistry for the 21st Century, C. G. Wermuth, N. Koga, and H. König, Eds., pp. 281–293, Metcalf Blackwell, Oxford, UK, 1994. View at Google Scholar
  31. A. Morikawa, D. M. Peereboom, Q. R. Smith et al., “Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer,” Journal of Clinical Oncology, vol. 31, no. 15, supplement 1, abstract 514, 2013, Proceedings of the 2013 ASCO Annual Meeting. View at Google Scholar
  32. Y. Dotsikas and Y. L. Loukas, “Efficient determination and evaluation of model cyclodextrin complex binding constants by electrospray mass spectrometry,” Journal of the American Society for Mass Spectrometry, vol. 14, no. 10, pp. 1123–1129, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Marangoci, M. Mares, M. Silion et al., “Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies,” Results in Pharma Sciences, vol. 1, no. 1, pp. 27–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. B. Cunniff and P. Vouros, “False positives and the detection of cyclodextrin inclusion complexes by electrospray mass spectrometry,” Journal of the American Society for Mass Spectrometry, vol. 6, no. 5, pp. 437–447, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Salvatierra, C. Jaime, A. Virgili, and F. Sánchez-Ferrando, “Determination of the inclusion geometry for the β-cyclodextrin/benzoic acid complex by NMR and molecular modeling,” Journal of Organic Chemistry, vol. 61, no. 26, pp. 9578–9581, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. Z.-I. Szabó, F. Mohammadhassan, L. Szőcs et al., “Stereoselective interactions and liquid chromatographic enantioseparation of thalidomide on cyclodextrin-bonded stationary phases,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 85, no. 3-4, pp. 227–236, 2016. View at Publisher · View at Google Scholar · View at Scopus